The Italian Embassy in Sweden, in collaboration with Angelini Pharma Nordics and Chiesi Nordic, subsidiaries of the renowned Italian pharmaceutical companies, and with the participation of the Italian Medicines Agency (Aifa) and the Swedish Medical Products Agency, held an 'Italy-Sweden Forum on Research and Innovation'.
This afternoon, at the residence of the Italian Ambassador in Stockholm, experts and representatives from the pharmaceutical sector gave an overview of the opportunities for exchange between the countries on the application of real world data in science, particularly pharmaceuticals and patient care. The event was moderated by Britta Stenson, Area Network Director for the Global Life Science Industry at Business Sweden.
"With almost 70,000 employees, Italy is among the world's leading pharmaceutical hubs, the leading producer of drugs in Europe," said Italy's ambassador to Sweden, Michele Pala. "The ability of companies to combine very high levels of quality, innovation, productivity supports the development of the sector, exports and the attraction of significant investments especially in R&D, amounting to approximately EUR 2 billion in 2022 alone," he added.
Fräs Anna Andersson, general manager at Angelini Pharma Nordics emphasised the company's commitment "to improve patient care outcomes through dialogue and collaboration. This Forum allows us to explore synergies between Italy and Sweden, using real data, data imaging and advanced technologies to drive innovation and meet healthcare challenges in a cohesive way," concluded Andersson.
Olav Fromm, Managing Director at Chiesi Nordic, also agrees on the importance of the collaboration: "I am looking forward to continuing and deepening the collaboration with other leading companies in the healthcare sector as well as with researchers who want to develop solutions for patients, whose care requires extra effort, by finding new solutions for a sustainable healthcare system. I am convinced that unity is strength," he said.
ALL RIGHTS RESERVED © Copyright ANSA
